Infliximab for psoriasis

This publication has 30 references indexed in Scilit:

• Clinical research helps elucidate the role of tumor necrosis factor-αin the pathogenesis of T1-mediated immune disorders: use of targeted immunotherapeutics as pathogenic probes
  Lupus, 2003
• Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris
  Journal of the American Academy of Dermatology, 2003
• Cytokines and autoimmunity
  Nature Reviews Immunology, 2002
• Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial
  The Lancet, 2001
• REVIEWCytokines and chemokines in the initiation and regulation of epidermal Langerhans cell mobilization
  British Journal of Dermatology, 2000
• Langerhans cells may trigger the psoriatic disease process via production of nitric oxide
  Immunology Today, 1997
• Dermal Dendritic Cells are Important Members of the Skin Immune System
  Published by Springer Nature ,1995
• Increased expression of adhesion receptors in both lesional and non-lesional psoriatic skin
  Archives of Dermatological Research, 1994
• Immunohistochemical Studies of Infiltrating Cells in Early and Chronic Lesions of Psoriasis
  The Journal of Dermatology, 1994
• Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro.
  The Journal of Experimental Medicine, 1985